Coiled-coil Based Drug-Free Macromolecular Therapeutics

基于卷曲线圈的无药大分子治疗

• 批准号: 8291234
• 负责人: JINDRICH H. KOPECEK
• 金额: $ 28.41万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8291234
• 关键词: Amino Acids; Animal Model; Antibodies; Antigen-Antibody Reactions; Antigens; Apoptosis; B-Cell NonHodgkins Lymphoma; B-Lymphocytes; Binding; Biological; Biological Assay; Biological Markers; Biological Process; CD20 Antigens; Cell Line; Cell surface; Cells; Charge; Cholecystokinin; Data; Diagnosis; Dose; Evaluation; Event; Exposure to; Fab Immunoglobulins; Frequencies; Goals; Immune response; Immunoglobulin Fragments; In Vitro; Incidence; Induction of Apoptosis; Lead; MS4A1 gene; Malignant Neoplasms; Mediating; Methods; Modality; Molecular Weight; Mus; Non-Hodgkin' s Lymphoma; Patients; Peptides; Pharmaceutical Preparations; Property; Protocols documentation; Roche brand of rituximab; Rodent; Structure; Surface; System; Testing; Therapeutic; Time; Toxic effect; Translating; Treatment Efficacy; United States; Validation; Vertebral column; base; biomaterial compatibility; cell type; copolymer; crosslink; design; improved; in vivo; methacrylamide; novel; novel strategies; novel therapeutics; receptor; therapeutic target; tositumomab; treatment strategy; tumor

DESCRIPTION (provided by applicant): Non-Hodgkin's lymphoma (NHL) is a prevalent cancer with an estimated 66,000 cases diagnosed in the United States in 2008, with the incidence doubling since 1980. Although treatments for NHLs greatly improved following the FDA approval of Rituxan, refractive malignancies still occur that are nonresponsive to current therapies in at least a third of all patients, indicating that improved treatment strategies are needed. One of the most reliable biomarkers and therapeutic targets for B cell NHL is CD20, which is a non- internalizing antigen that remains on the cell surface when bound to a complementary antibody. The crosslinking of CD20-bound antibodies with a secondary antibody results in apoptosis of these cells. The overall goal of this project is to generate new, drug-free macromolecular therapeutics for improved treatment of NHL. A new apoptosis induction system is proposed which is based on N-(2- hydroxypropyl)methacrylamide (HPMA) graft copolymer mediated formation of coiled-coil heterodimers at B- cell surface. The rationale of the design is the absence of low molecular weight drugs and the fact that crosslinking of CD20 at B-cell surface results in apoptosis. The system is composed of a pair of complementary coiled-coil peptides forming antiparallel heterodimers; Fab' fragment of the 1F5 anti-CD20 antibody; and HPMA copolymer. One peptide is conjugated to the Fab' fragment, the other is conjugated in multiple grafts to polyHPMA. A pair of oppositely charged pentaheptad peptides (CCE and CCK) that formed antiparallel coiled-coil heterodimers with a high degree of biorecognition was previously designed. It was hypothesized that the unique biorecognition of CCK and CCE peptides could be a basis for the design of a novel class of macromolecular therapeutics. Indeed, the exposure of CD20+ Raji B cells to Fab'-CCE resulted in the decoration of the cell surface with multiple copies of the CCE peptide via antigen-antibody fragment biorecognition. Further exposure of the CCE decorated cells to HPMA copolymer grafted with multiple copies of CCK resulted in the formation of CCE-CCK coiled-coil heterodimers on the cell surface. This second biorecognition event induced crosslinking of CD20 receptors and triggered apoptosis of Raji B cells. The system will be optimized based on the preliminary data. Shorter coiled-coil forming sequences containing L- and/or D-amino acid residues will be designed and evaluated. HPMA graft copolymer mediated coiled-coil formation at cell surface with concomitant receptor crosslinking and apoptosis induction will be assessed in vitro using five cell types and three apoptosis assays. Importantly, the efficacy and biocompatibility of drug-free macromolecular therapeutics will be evaluated in an animal model. Body distribution, impact of the dose and frequency of administration on the efficacy of treatment will be evaluated with the aim to select leading compound(s) and optimal treatment modalities. Finally, this new concept will be developed into a new therapeutic entity, drug-free macromolecular therapeutics.

描述（由申请人提供）：非霍奇金淋巴瘤 (NHL) 是一种流行的癌症，2008 年美国估计诊断出 66,000 例病例，自 1980 年以来发病率翻了一番。尽管 FDA 批准 Rituxan 后，NHL 的治疗大大改善至少有三分之一的患者仍然存在对当前治疗无反应的屈光恶性肿瘤，这表明需要改进的治疗策略。 B 细胞 NHL 最可靠的生物标志物和治疗靶点之一是 CD20，它是一种非内化抗原，当与互补抗体结合时保留在细胞表面。 CD20 结合抗体与二抗的交联导致这些细胞凋亡。该项目的总体目标是开发新的、无药物的大分子疗法，以改善 NHL 的治疗。提出了一种新的细胞凋亡诱导系统，其基于N-(2-羟丙基)甲基丙烯酰胺(HPMA)接枝共聚物介导的B细胞表面卷曲螺旋异二聚体的形成。该设计的基本原理是不使用低分子量药物，并且 CD20 在 B 细胞表面的交联会导致细胞凋亡。该系统由一对互补的卷曲螺旋肽组成，形成反向平行异二聚体； 1F5抗CD20抗体的Fab'片段；和 HPMA 共聚物。一种肽与 Fab' 片段缀合，另一种肽在多个移植物中与聚 HPMA 缀合。先前设计了一对带相反电荷的五七肽（CCE 和 CCK），它们形成具有高度生物识别性的反向平行卷曲螺旋异二聚体。据推测，CCK 和 CCE 肽的独特生物识别可以成为设计一类新型大分子疗法的基础。事实上，将 CD20+ Raji B 细胞暴露于 Fab'-CCE 会导致细胞表面通过抗原抗体片段生物识别被多个 CCE 肽拷贝修饰。将 CCE 修饰的细胞进一步暴露于接枝有多个 CCK 拷贝的 HPMA 共聚物，导致在细胞表面形成 CCE-CCK 卷曲螺旋异二聚体。第二次生物识别事件诱导 CD20 受体交联并引发 Raji B 细胞凋亡。系统将根据初步数据进行优化。将设计和评估包含L-和/或D-氨基酸残基的较短卷曲螺旋形成序列。 HPMA 接枝共聚物介导的细胞表面卷曲螺旋形成以及伴随的受体交联和细胞凋亡诱导将在体外使用五种细胞类型和三种细胞凋亡测定进行评估。重要的是，无药大分子疗法的功效和生物相容性将在动物模型中进行评估。将评估身体分布、剂量和给药频率对治疗功效的影响，以选择主要化合物和最佳治疗方式。最终，这一新概念将发展成为一种新的治疗实体，即无药大分子疗法。